Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Naiyer A. Rizvi , Julien Mazières , David Planchard +27 more 2015 The Lancet Oncology 1406 citations
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Edward B. Garon , Tudor‐Eliade Ciuleanu , Óscar Arrieta +23 more 2014 The Lancet 1263 citations